Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701)

被引：0
|
作者：
Koki Nakanishi
Daisuke Kobayashi
Yoshinari Mochizuki
Kiyoshi Ishigure
Seiji Ito
Hiroshi Kojima
Akiharu Ishiyama
Shinichi Fujitake
Toshio Shikano
Satoshi Morita
Yasuhiro Kodera
机构：
[1] Komaki City Hospital,Department of Surgery
[2] Nagoya University Graduate School of Medicine,Department of Gastroenterological Surgery
[3] Konan Kosei Hospital,Department of Surgery
[4] Aichi Cancer Center,Department of Gastroenterological Surgery
[5] Aichi Cancer Center Hospital,Department of Surgery
[6] Okazaki City Hospital,Department of Surgery
[7] Nishio Municipal Hospital,Department of Surgery
[8] Yokkaichi Municipal Hospital,Department of Surgery
[9] Kyoto University Graduate School of Medicine,Department of Biomedical Statistics and Bioinformatics
来源：
International Journal of Clinical Oncology | 2016年 / 21卷
关键词：
Gastric cancer; S-1; Paclitaxel; Second-line chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：557 / 565
页数：8
相关论文
共 50 条
  • [1] Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701)
    Nakanishi, Koki
    Kobayashi, Daisuke
    Mochizuki, Yoshinari
    Ishigure, Kiyoshi
    Ito, Seiji
    Kojima, Hiroshi
    Ishiyama, Akiharu
    Fujitake, Shinichi
    Shikano, Toshio
    Morita, Satoshi
    Kodera, Yasuhiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2016, 21 (03) : 557 - 565
  • [2] Randomized Phase II Trial of S-1 plus Irinotecan Versus S-1 plus Paclitaxel as First-line Treatment for Advanced Gastric Cancer (OGSG0402)
    Sugimoto, Naotoshi
    Fujitani, Kazumasa
    Imamura, Hiroshi
    Uedo, Noriya
    Iijima, Shohei
    Imano, Motohiro
    Shimokawa, Toshio
    Kurokawa, Yukinori
    Furukawa, Hiroshi
    Goto, Masahiro
    ANTICANCER RESEARCH, 2014, 34 (02) : 851 - 857
  • [3] RANDOMIZED PHASE II TRIAL OF S-1 PLUS IRINOTECAN VERSUS S-1 PLUS PACLITAXEL AS FIRST-LINE TREATMENT FOR ADVANCED GASTRIC CANCER (OGSG0402)
    Fujitani, K.
    Takiuchi, H.
    Sugimoto, N.
    Imamura, H.
    Iijima, S.
    Imano, M.
    Kimura, Y.
    Kurokawa, Y.
    Tsujinaka, T.
    Furukawa, H.
    ANNALS OF ONCOLOGY, 2010, 21 : 256 - 256
  • [4] Phase II Study of S-1 Monotherapy as a First-line, Combination Therapy of S-1 plus Cisplatin as a Second-line, and Weekly Paclitaxel Monotherapy as a Third-line Therapy in Patients with Advanced Gastric Carcinoma Phase II Study of S-1, S-1 plus Cisplatin, and Weekly Paclitaxel in Patients with Advanced Gastric Carcinoma
    Rino, Yasushi
    Yukawa, Norio
    Wada, Nobuyuki
    Suzuki, Makoto
    Murakami, Hitoshi
    Yamada, Takanobu
    Nakayama, Hirotaka
    Yamamoto, Naoto
    Sato, Tsutomu
    Yamada, Roppei
    Ohshima, Takashi
    Masuda, Munetaka
    Imada, Toshio
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2008, 2 : 375 - 383
  • [5] Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer
    X. Wang
    M. L. Wang
    L. Y. Zhou
    X. Y. Lu
    J. F. Yang
    H. G. Yu
    Clinical and Translational Oncology, 2013, 15 : 836 - 842
  • [6] Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer
    Wang, X.
    Wang, M. L.
    Zhou, L. Y.
    Lu, X. Y.
    Yang, J. F.
    Yu, H. G.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (10): : 836 - 842
  • [7] Phase III study comparing intraperitoneal paclitaxel plus S-1/paclitaxel with S-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial
    Fujiwara, Y.
    Ishigami, H.
    Fukushima, R.
    Nashimoto, A.
    Yabusaki, H.
    Imamoto, H.
    Imano, M.
    Kodera, Y.
    Uenosono, Y.
    Amagai, K.
    Kadowaki, S.
    Miwa, H.
    Yamaguchi, H.
    Yamaguchi, T.
    Kitayama, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study
    Yulong Zheng
    Weijia Fang
    Chenyu Mao
    Joing Qian
    Peng Zhao
    Xiaochen Zhang
    Haiping Jiang
    Yi Zheng
    Nong Xu
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 503 - 509
  • [9] Biweekly S-1 plus paclitaxel (SPA) as second-line chemotherapy after failure from fluoropyrimidine and platinum in advanced gastric cancer: a phase II study
    Zheng, Yulong
    Fang, Weijia
    Mao, Chenyu
    Qian, Joing
    Zhao, Peng
    Zhang, Xiaochen
    Jiang, Haiping
    Zheng, Yi
    Xu, Nong
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (03) : 503 - 509
  • [10] Phase II study of S-1 as a first-line, S-1 plus cisplatin as a second-line, and weekly paclitaxel as a third-line therapy in patients with advanced gastric carcinoma
    Yamada, T.
    Rino, Y.
    Kanari, M.
    Saeki, H.
    Yukawa, N.
    Wada, N.
    Ooshima, T.
    Yamada, R.
    Haruhiko, C.
    Masuda, M.
    Imada, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345